Immutep (IMMP) announces it has received a EUR 2,588,954 research and development tax incentive payment in cash from the French Government under its Credit d’Impot Recherche scheme, CIR. The “Credit d’Impot Recherche,” meaning “Research Tax Credit,” is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep Advances Key Clinical Trials and Strengthens Financial Position
- Immutep reports Q1 cash receipts from customers A$15,000
- Immutep Showcases Promising Lung Cancer Treatment Results at ESMO Congress 2025
- Immutep Announces Breakthrough Results in Soft Tissue Sarcoma Trial
- Immutep presents two posters at ESMO on changing landscape for 1L NSCLC